Patents by Inventor John L. LaMattina

John L. LaMattina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6486182
    Abstract: This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 26, 2002
    Assignee: Pfizer Inc
    Inventors: George Chang, Ernest S. Hamanaka, John L. LaMattina
  • Patent number: 5026715
    Abstract: 2-Guanidino-4-arylthiazole compounds of the formula ##STR1## a pharmaceutically acceptable cationic or acid addition salt thereof whereinR.sup.1 is hydrogen, (C.sub.1 -C.sub.10)alkyl, optionally substituted phenyl or certain optionally substituted aralkyl groups;R.sup.2 is hydrogen or (C.sub.1 -C.sub.4)alkyl, andAr is certain optionally substituted pyrrolyl or indolyl groups; method for their use in treatment of gastric ulcers, by inhibition of parietal cell H.sup.+ /K.sup.+ ATPase, and antiinflammatory conditions in combination with piroxicam, for use in mammals, and pharmaceutical compositions containing said compounds.
    Type: Grant
    Filed: October 20, 1989
    Date of Patent: June 25, 1991
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Peter A. McCarthy, Lawrence A. Reiter
  • Patent number: 4910204
    Abstract: A compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen; R.sup.2 is (C.sub.1 -C.sub.15) alkyl, (C.sub.3 -C.sub.15)alkenyl, phenyl, substituted phenyl, (C.sub.7 -C.sub.20)-phenylalkyl, or substituted (C.sub.7 -C.sub.20)phenylalkyl wherein the substituents on the substituted phenyl and substituted phenylalkyl are independently one or two of fluoro, chloro, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3 alkoxy, and trifluoromethyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a pyrrolodinyl, substituted pyrrolidinyl, piperidyl or substituted piperidyl group, wherein the substituents on said substituted pyrrolidinyl and piperidyl groups are independently one of (C.sub.1 -C.sub.6)alkyl, phenyl, and (C.sub.7 -C.sub.9)phenylalkyl; and R.sup.3 is hydrogen, (C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, (C.sub.7 -C.sub.9)phenylalkyl, or substituted (C.sub.7 -C.sub.
    Type: Grant
    Filed: June 28, 1988
    Date of Patent: March 20, 1990
    Assignee: Pfizer Inc.
    Inventors: Frederick J. Walker, John L. LaMattina, Brian T. O'Neill
  • Patent number: 4711888
    Abstract: 2-Amino-4-substituted-5-(hydroxy or alkoxy)pyrimidines, which may be 6-substituted, and derivatives thereof are inhibitors of leukotriene synthesis and are therefore useful for the treatment of pulmonary, inflammatory, allergic and cardiovascular diseases. The compounds are also cytoprotective and therefore useful in the treatment of peptic ulcers.
    Type: Grant
    Filed: July 24, 1985
    Date of Patent: December 8, 1987
    Assignee: Pfizer Inc.
    Inventors: Frederick J. Walker, John L. LaMattina
  • Patent number: 4673677
    Abstract: A method for the treatment of gastrointestinal disorders in a patient which comprises administering to the patient a gastric anti-secretory effective amount of a 2-amino-5-hydroxy-4-methylpyrimidine or a substituted amino derivative thereof, optionally in admixture with an additional gastric anti-secretory agent.
    Type: Grant
    Filed: August 9, 1985
    Date of Patent: June 16, 1987
    Assignee: Pfizer Inc.
    Inventor: John L. LaMattina
  • Patent number: 4636498
    Abstract: An improved antiinflammatory composition and method of treating inflammation which employs a combination of an antiinflammatory agent (e.g. indomethacin or an oxicam) with a histamine-H.sub.2 antagonist selected from the group consisting of 2-guanidino-4-(4-imidazolyl)thiazole, 2-guanidino-4-(2-methyl-4-imidazolyl )thiazole, 2-(N-benzyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole, 2-(N-pentyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and 2-guanidino-4-[2-(hexylamino)-4-imidazolyl]thiazole.
    Type: Grant
    Filed: August 15, 1985
    Date of Patent: January 13, 1987
    Assignee: Pfizer Inc.
    Inventor: John L. LaMattina
  • Patent number: 4590299
    Abstract: A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.
    Type: Grant
    Filed: February 11, 1985
    Date of Patent: May 20, 1986
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Christopher A. Lipinski
  • Patent number: 4554276
    Abstract: Novel 2-amino-5-hydroxy-4-methylpyrimidines and substituted amino derivatives thereof useful as inhibitors of leukotriene synthesis for the treatment of pulmonary, inflammatory and cardiovascular diseases, cancer and psoriasis. In addition these compounds are cytoprotective and therefore useful in the treatment of peptic ulcers. A process for the preparation of such active compounds by ring rearrangement of 2-amino-5-acetyloxazole, pharmaceutical compositions containing the novel active compounds and compositions containing these compounds in combination with other anti-inflammatory agents or gastric anti-secretory agents.
    Type: Grant
    Filed: October 3, 1983
    Date of Patent: November 19, 1985
    Assignee: Pfizer Inc.
    Inventor: John L. LaMattina
  • Patent number: 4510313
    Abstract: A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.
    Type: Grant
    Filed: March 27, 1984
    Date of Patent: April 9, 1985
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Christopher A. Lipinski
  • Patent number: 4452987
    Abstract: A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.
    Type: Grant
    Filed: December 13, 1982
    Date of Patent: June 5, 1984
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Christopher A. Lipinski
  • Patent number: 4443621
    Abstract: p-Nitrophenyl 3-bromo-2,2-diethoxypropionate, useful in the synthesis of highly functionalized small molecules and heterocycles, including pyromeconic acid and 6-methylpyromeconic acid.
    Type: Grant
    Filed: March 14, 1983
    Date of Patent: April 17, 1984
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Paul D. Weeks
  • Patent number: 4435396
    Abstract: Heretofore unavailable 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; a novel process therefor, also advantageous for the preparation of known antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; intermediate compounds therefor; and a method for treatment of ulcers in mammals therewith.
    Type: Grant
    Filed: May 10, 1982
    Date of Patent: March 6, 1984
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Christopher A. Lipinski
  • Patent number: 4302464
    Abstract: A series of 2-substituted-4-(4-imidazolyl)pyridines and the pharmaceutically acceptable acid addition salts thereof as histamine H.sub.2 -receptor inhibitors for controlling gastric acidity.
    Type: Grant
    Filed: October 16, 1980
    Date of Patent: November 24, 1981
    Assignee: Pfizer Inc.
    Inventors: John L. LaMattina, Christopher A. Lipinski